SBIR/STTR Research Award
Smart Toilet with Artificial Intelligence for Remote Management of Inflammatory Bowel Disease
Award amount
$349,877Program and phase
STTR · Phase IAward year
2022Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- COPRATA INC
- Proposal award date
- 2022-04-01
- Contract end date
- 2023-03-31
- UEI
- KW9HMURNKJN5
- Solicitation number
- PA21-262
- Topic code
- 300
Research abstract
ABSTRACT
Inflammatory Bowel Disease (IBD) affects three million US adults and, due to chronicity, requires
lifelong medical care, negatively impacts patient quality of life, and results in large healthcare
costs. The disease course is characterized by remissions and flare-ups, thus disease
management by medication and dietary interventions requires frequent monitoring. Less invasive
than endoscopy, longitudinal tracking of the fecal biomarker calprotectin is increasingly used to
achieve and maintain remission. Remote disease management through app-based diaries of
bowel movements to assess disease activity and at-home measurement of calprotectin have been
found effective when implemented consistently; however, patient adherence is as low as 30%.
We propose a technology that enables automatic and seamless monitoring of bowel movements
and calprotectin, thereby greatly increasing patient adherence to tracking regimens. The
innovation is a Smart Sampling Toilet system: an engineered portal retrofitted to a conventional
toilet that, discreetly and post-flush, inspects stool appearance and enables hands-free stool
sampling for analysis. The system has been demonstrated in the laboratory with human stool
specimens across the range of stool forms, including loose stools. An artificial intelligence (AI)
method has been developed for stool image analysis and classification.
The objective of this study is to demonstrate feasibility of onsite measurement of calprotectin by
the Smart Sampling Toilet, a prototype system for use by human subjects that integrates stool
morphology analysis. Specific Aim 1 is a benchtop study using commercial lateral flow assays to
assess sensitivity and specificity of calprotectin measurements from stool sampled through the
engineered portal. After a spiking study, we will measure calprotectin on clinical specimens from
patients with IBD through a collaboration with the Duke University Gastroenterology IBD Clinic.
In Specific Aim 2, we will deploy a Smart Toilet prototype outside of the laboratory for use by
human subjects to refine the AI algorithm for stool morphology classification. We will evaluate
specimens both from healthy subjects using the toilet and from flushing clinical specimens
obtained from IBD patients.
The data obtained in this study will be the basis for a Phase 2 study with the Smart Toilet system
installed for use by patients through the Duke IBD clinic. Ultimately, we envision Smart Toilet
systems installed in the home to benefit IBD disease management and improve patient quality of
life by removing barriers to stool-data access and enabling improved clinical outcomes.Project Narrative
Remote management of Inflammatory Bowel Disease holds promise of achieving health
outcomes while being efficient and convenient for patients; however, studies show that patient
adherence to a regimen requiring daily recording of bowel movements and frequent use of stool
collection kits is low (andlt; 30%). Our proposed approach combines toilet-adapting hardware and
artificial intelligence to make daily stool monitoring automatic and seamless. Our unobtrusive
solution will provide objective longitudinal data to inform treatment decisions, a significant step
toward improving quality of life and health outcomes for patients suffering from chronic
gastrointestinal diseases.
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- A platform for T-cell receptor mimic antibody generation modeled using pHLA-A*11:01 KRAS G12D
- Combinatorial pipeline for discovery of anti-GPCR Nanobodies
- Development of a GBP-based glycosylation analysis system
- Extended-release injectable gel for multi-day treatment of postoperative pain
- eMOA: A Multi-Omic Service for Mechanism of Action Determination in Drug Screening